[1]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13
[PubMed PMID: 29133356]
Level 1 (high-level) evidence
[2]
Langan J, Rodríguez-Mañas L, Sareli P, Heinig R. Nisoldipine CC: clinical experience in hypertension. Cardiology. 1997:88 Suppl 1():56-62; discussion 63-5
[PubMed PMID: 9118169]
[3]
Lenz TL, Wurdeman RL, Hilleman DE. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. Pharmacotherapy. 2001 Aug:21(8):898-903
[PubMed PMID: 11718496]
[4]
Thadani U, Zellner SR, Glasser S, Bittar N, Montoro R, Miller AB, Chaitman B, Schulman P, Stahl A, DiBianco R. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991 Dec:84(6):2398-408
[PubMed PMID: 1959195]
Level 2 (mid-level) evidence
[5]
Chen YH, Liu RC, Wang SP. Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed. 1996 Nov:58(5):323-8
[PubMed PMID: 9037847]
Level 1 (high-level) evidence
[6]
Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. International journal of molecular sciences. 2021 Dec 10:22(24):. doi: 10.3390/ijms222413302. Epub 2021 Dec 10
[PubMed PMID: 34948113]
[7]
El Maghraby GM, Elsergany RN. Fast disintegrating tablets of nisoldipine for intra-oral administration. Pharmaceutical development and technology. 2014 Sep:19(6):641-50. doi: 10.3109/10837450.2013.813543. Epub 2013 Jul 10
[PubMed PMID: 23841582]
[8]
Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Molecular psychiatry. 2022 Sep:27(9):3904-3912. doi: 10.1038/s41380-022-01615-6. Epub 2022 May 26
[PubMed PMID: 35618884]
[10]
Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug development and industrial pharmacy. 2015:41(12):1968-77. doi: 10.3109/03639045.2015.1024685. Epub 2015 Apr 1
[PubMed PMID: 25830370]
[11]
Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomedicine, and biotechnology. 2018:46(sup2):616-625. doi: 10.1080/21691401.2018.1465068. Epub 2018 Apr 24
[PubMed PMID: 29688077]
Level 2 (mid-level) evidence
[12]
Rameis H. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. Wiener medizinische Wochenschrift (1946). 1993:143(19-20):490-500
[PubMed PMID: 8135031]
[13]
Shah A, Krol G, Sundaresan P, Lettieri J, Falk R, Lasseter K, Heller AH. Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis. American journal of therapeutics. 1995 Jan:2(1):15-19
[PubMed PMID: 11850642]
[14]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub
[PubMed PMID: 30575676]
[16]
White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. American journal of hypertension. 2003 Sep:16(9 Pt 1):739-45
[PubMed PMID: 12944032]
Level 2 (mid-level) evidence
[17]
Tajani AH, Nesbitt SD. Gingival hyperplasia in a patient with hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2008 Nov:10(11):863-5. doi: 10.1111/j.1751-7176.2008.00036.x. Epub
[PubMed PMID: 19128276]
[18]
Kim S, Yu YM, Kwon J, Yoo H, Jung SH, Lee E. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review. International journal of environmental research and public health. 2019 Apr 13:16(8):. doi: 10.3390/ijerph16081333. Epub 2019 Apr 13
[PubMed PMID: 31013922]
Level 1 (high-level) evidence
[19]
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. British journal of clinical pharmacology. 2006 Mar:61(3):246-55
[PubMed PMID: 16487217]
[20]
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Oct 1:63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10
[PubMed PMID: 27516382]
Level 1 (high-level) evidence
[21]
Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-biological interactions. 2019 Jun 1:306():1-9. doi: 10.1016/j.cbi.2019.04.005. Epub 2019 Apr 6
[PubMed PMID: 30965050]
[22]
Guengerich FP. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomolecules & therapeutics. 2022 Jan 1:30(1):1-18. doi: 10.4062/biomolther.2021.102. Epub
[PubMed PMID: 34475272]
[23]
Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Therapeutics and clinical risk management. 2014:10():355-62. doi: 10.2147/TCRM.S47632. Epub 2014 May 14
[PubMed PMID: 24868161]
[24]
Prieto-Garcia JM, Graham L, Alkhabbaz O, Mazzari ALDA. Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review. Plants (Basel, Switzerland). 2023 Jan 31:12(3):. doi: 10.3390/plants12030623. Epub 2023 Jan 31
[PubMed PMID: 36771707]
Level 2 (mid-level) evidence
[25]
Turcu AF, White JA, Kulaga ME, Skluth M, Gruss CB. Calcium channel blocker-associated small bowel angioedema. Journal of clinical gastroenterology. 2009 Apr:43(4):338-41. doi: 10.1097/MCG.0b013e31815cf6b9. Epub
[PubMed PMID: 19077729]
[26]
Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2004:4(5):281-97
[PubMed PMID: 15449971]
[27]
Stouras I, Papaioannou TG, Tsioufis K, Eliopoulos AG, Sanoudou D. The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare. Journal of personalized medicine. 2022 Mar 22:12(4):. doi: 10.3390/jpm12040513. Epub 2022 Mar 22
[PubMed PMID: 35455629]
[28]
St-Onge M, Dubé PA, Gosselin S, Guimont C, Godwin J, Archambault PM, Chauny JM, Frenette AJ, Darveau M, Le Sage N, Poitras J, Provencher J, Juurlink DN, Blais R. Treatment for calcium channel blocker poisoning: a systematic review. Clinical toxicology (Philadelphia, Pa.). 2014 Nov:52(9):926-44. doi: 10.3109/15563650.2014.965827. Epub 2014 Oct 6
[PubMed PMID: 25283255]
Level 1 (high-level) evidence
[29]
Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, Guan J, Lam K, Luke MJ, Read SH, Stall NM, Wu W, Zhu L, Rochon PA, McCarthy LM. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA internal medicine. 2020 May 1:180(5):643-651. doi: 10.1001/jamainternmed.2019.7087. Epub
[PubMed PMID: 32091538]
[30]
WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15:128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5
[PubMed PMID: 23741058]
Level 1 (high-level) evidence
[31]
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Sep 10:74(10):e177-e232. doi: 10.1016/j.jacc.2019.03.010. Epub 2019 Mar 17
[PubMed PMID: 30894318]
Level 1 (high-level) evidence
[32]
Wachowiak R, Strach B, Lopatka P. [Toxicological analysis of selected 1,4-dihydropyridine calcium channel blockers in the diagnosis of intoxications]. Archiwum medycyny sadowej i kryminologii. 2005 Jan-Mar:55(1):47-54
[PubMed PMID: 15984121]
[33]
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Sep 10:74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17
[PubMed PMID: 30894319]
Level 1 (high-level) evidence